Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with
AD, certain small substances stick together. This leads to changes in thinking and behaviour.
The company PRInnovation is developing a new treatment for Alzheimer's disease, called
PRI-002. It is thought that PRI-002 can cut the sticked substances back into small pieces.
That would reduce the effects of Alzheimer's disease. In the current study the investigators
examine whether PRI-002 is safe and effective in participants with mild cognitive impairment
(MCI) or mild dementia due to AD.
Phase:
Phase 2
Details
Lead Sponsor:
PRInnovation GmbH
Collaborators:
Federal Agency for Disruptive Innovation - SPRIN-D Julius Clinical Priavoid